Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant the accuracy of the data and the conclusions drawn. Authors must ensure that all research works are original works, and contributions are attributed appropriately. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice:)
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Transoral or Parapharyngeal Approach to Remove Sporadic Skull Base Schwannoma. R.E. FRIEDRICH (Hamburg, Germany) ......................................................................................................................... 4557

Postoperative Pelvic Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC) for High-risk or Recurrent Prostate Cancer. M.I. KOUKOURAKIS, A. PAPADOPOULOU, I. ABATZOGLOU, M. PANTELIADOU, K. SISMANIDOU, S. TOULOUPIDIS (Alexandroupolis, Greece) .............................................................. 4561


Inflammation-based Prognostic Score as a Predictor of Postoperative Gastric Cancer Recurrence. Y. MOHRI, K. TANAKA, M. OHI, Y. TOIYAMA, H. YASUDA, Y. INOUE, K. UCHIDA, M. KUSUNOKI (Tsu, Mie, Japan) ............................................................................................................................... 4581

Duration of Adjuvant Trastuzumab Treatment in Routine Practice. M. MONTSERRAT, D. LEVEQUE, P. BARTHELEM, J.P. BERGERAT (Strasbourg, France) .......................................................................................... 4585

Association between Expression of Thymidylate Synthase, Dihydrofolate Reductase, and Glycinamide Ribonucleotide Formyltransferase, and Efficacy of Pemetrexed in Advanced Non-small Cell Lung Cancer. T. SHIMIZU, Y. NAKANISHI, Y. NAKAGAWA, I. TSUJINO, N. TAKAHASHI, N. NEMOTO, S. HASHIMOTO (Tokyo, Japan) ........................................................................................................ 4589

Radiotherapy as an Effective Primary Treatment for Epithelioid Haemangioendothelioma of the Cervical Spine. K.-L. YIM, V.P. SUMATHI, D. SPOONER (Birmingham, UK) ................................................................. 4597

Plasma TIMP1 Level Is a Prognostic Factor in Patients with Liver Metastases. K. BUNATOVA, M. PESTA, V. KULDA, O. TOPOLCAN, J. VRZALOVA, A. SUTNAR, V. TRESKA, L. PECEN, V. LISKA (Prague, Czech Republic) ........................................................................................................ 4601

Ipilimumab-induced Immune-related Renal Failure – A Case Report. P.M. FORDE, K. ROCK, G. WILSON, K.J. O’BYRNE (Baltimore, MD, USA; Dublin, Ireland) ...................................................................... 4607

Reviews (pages 4171, 4193, 4201, 4213, 4225, 4235, 4245)
Perianal Paget’s Disease: A Case Report and Literature Review. M. VERGATI, V. FILINGERI, G. PALMIERI, M. ROSELLI (Rome, Italy) ................................................................. 4461

Diffusion-weighted MRI and PSA Correlations in Patients with Prostate Cancer Treated with Radiation and Hormonal Therapy. Y. IRAHA, S. MURAYAMA, A. KAMIYA, S. IRAHA, K. OGAWA (Okinawa; Osaka, Japan) ................................................................. 4467

Combination Chemotherapy of Alternating Etoposide and Carboplatin with Weekly Administration of Irinotecan and Cisplatin in Extensive-stage Small-cell Lung Cancer. A. YOSHIMURA, R. NORO, A. MIYANAGA, H. MIZUTANI, S. KOSAIHIRA, Y. MINEGISHI, M. SEIKE, M. HINO, M. ANDO, K. NOMURA, T. OKANO, K. KOBAYASHI, A. GEMMA, THE EAST JAPAN CHESTERS GROUP (Tokyo; Chiba; Fukushima; Saitama, Japan) ................................................................. 4473

Wilms’ Tumor-1 Transcript in Peripheral Blood Helps Diagnose Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients with Pancytopenia. T. YAMAUCHI, Y. MATSUDA, M. TAKAI, T. TASAKI, N. HOSONO, E. NEGORO, S. IKEGAYA, K. TAKAGI, S. KISHI, A. YOSHIDA, Y. URASAKI, T. UEDA (Fukui, Japan) ................................................................. 4479


Expression of Macrophage Migration-Inhibitory Factor Is Correlated with Progression in Oral Cavity Carcinomas. N. KINDT, J. LECHIEN, C. DECAESTECKER, A. RODRIGUEZ, G. CHANTRAIN, M. REMMELINK, G. LAURENT, H.-J. GABIGUS, S. SAUSSEZ (Mons; Brussels, Belgium; Munich, Germany) ................................................................. 4499

Increased Incidence of a Second Lymphoproliferative Malignancy in Patients with Multiple Myeloma - a SEER based Study. S. CHAKRABORTY, R.J. HAUKE, N. BONTHU, S.R. TARANTOLO (Omaha, NE; Salem, MA, USA) ................................................................. 4507

Clinical Outcome of Patients with Advanced Ovarian Cancer after Resection of Liver Metastases. U.P. NEUMANN, C. FOTOPOULOU, M. SCHMEDING, A. THELEN, G. PAPANIKOLAOU, E.I. BRAICU, P. NEUHAUS, J. SEHOULI (Berlin; Aachen, Germany) ................................................................. 4517


Clinical Outcomes of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK Rearrangement. H. HAYASHI, I. OKAMOTO, H. KIMURA, K. SAKAI, Y. NISHIMURA, K. NISHIO, K. NAKAGAWA (Osaka, Japan) ................................................................. 4533

Final Results of an International Retrospective Observational Study in Patients with Advanced Breast Cancer Treated with Oral Vinorelbine-based Chemotherapy. A. GARCIA PALOMO, I. GLOGOWSKA, H. SOMMER, N. MALAMOS, E. KILAR, J. LOPEZ VEGA, L. TORRECILLAS, T. DELOZIER, J. ETTL, J. FINEK (Leon; Santander, Spain; Warsaw; Swidnica, Poland; Munich, Germany; Athens, Greece; Mexico DF, Mexico; Caen, France; Pilsen, Czech Republic) ................................................................. 4539


Contents continued on the preceding page
Tissue Distribution of (Lipocurc™) Liposomal Curcumin and Tetrahydrocurcumin Following Two- and Eight-hour Infusions in Beagle Dogs. D. MATABUDUL, K. PUCAJ, G. BOLGER, B. VCELAR, M. MAJEED, L. HELSON (Scarborough, ON, Canada; Klosterneuberg, Austria; East Windsor, NJ; Quakertown, PA, USA) ................................................................. 4359

Infusion Pharmacokinetics of Lipocurc™ (Liposomal Curcumin) and its Metabolite Tetrahydrocurcumin in Beagle Dogs. L. HELSON, G. BOLGER, M. MAJEED, B. VCELAR, K. PUCAJ, D. MATABUDUL (Quakertown, PA; East Windsor, NJ, USA; Scarborough, ON, Canada; Klosterneuberg, Austria) ................................................................. 4365

FBN2 Methylation Is Detected in the Serum of Colorectal Cancer Patients with Hepatic Metastasis. K. HIBI, H. MIZUKAMI, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan) .................................................. 4371

Loss of Expression of Growth Differentiation Factor-9 (GDF9) in Human Kidney Cancer and Regulation of Growth and Migration of Kidney Cancer Cells by GDF9. P. DU, L. YE, H. LI, F. RUGE, Y. YANG, W.G. JIANG (Cardiff, UK; Beijing, PR China) ................................................................. 4375

Interference with ATP5 Function Enhances the Sensitivity of Human Pancreatic Cancer Cells to Paclitaxel-induced Apoptosis. M. HU, B. WANG, D. QIAN, L. LI, L. ZHANG, X. SONG, D.X. LIU (Qingdao, Shandong, China; Hershey, PA, USA) ................................................................. 4385

Synergism in Concomitant Chemoradiotherapy of Cisplatin and Oxaliplatin and their Liposomal Formulation in Human Colorectal Cancer HCT116 Model. T. TIPPAYAMONTRI, R. KOTB, B. PAQUETTE, L. SANCHE (Sherbrooke, QC, Canada) ................................................................. 4395

Dermokine Expression in Intraductal Papillary-Mucinous Neoplasm and Invasive Pancreatic Carcinoma. K. WATANABE, T. OCHOHAI, S. KIKUCHI, T. KUMANO, T. MATSUI, K. MORIMOTO, S. YASUKAWA, S. NAKAMORI, M. SASAKO, A. KANAGAWA, E. OTSUI (Kyoto; Nishinomiya; Osaka, Japan) ................................................................. 4405

Effects of Ellagic Acid on Chemosensitivity to 5-Fluorouracil in Colorectal Carcinoma Cells. T.-Y. KAO, Y.-C. CHUNG, Y.-C. HOU, Y.-W. TSAI, C.-H. CHEN, H.-P. CHANG, J.-L. CHOU, C.-P. HSU (Hsin-Chu; Taichung, Taiwan, ROC) ................................................................. 4413

Kinase Inhibition by the Jamaican Ball Moss, Tillandsia recurvata L. H.I.C. LOWE, C.T. WATSON, S. BADAL, N.J. TOYANG, J. BRYANT (Kingston; Mona, Jamaica; Baltimore, MD; Lauderhill, FL, USA) ................................................................. 4419

Adva-27a, a Novel Podophyllotoxin Derivative Found To Be Effective against Multidrug Resistant Human Cancer Cells. A. MERZOUKI, M.D. BUSCHMANN, M. JEAN, R.S. YOUNG, S. LIAO, S. GAL, Z. LI, S.N. SLILATY (Montreal, QC, Canada; Binghamton, NY, USA) ................................................................. 4423


Decitabine, a DNA Methyltransferase Inhibitor, Reduces P-Glycoprotein mRNA and Protein Expressions and Increases Drug Sensitivity in Drug-resistant MOLT4 and Jurkat Cell Lines. K. ONDA, R. SUZUKI, S. TANAKA, H. OGA, K. OKA, T. HIRANO (Tokyo, Japan) ................................................................. 4439

Modulation of P-Glycoprotein Expression by Honokiol, Magnolol and 4-O-Methylhonokiol, the Bioactive Components of Magnolia officinalis. H.-K. HAN, L.T. VAN ANH (Seoul, South Korea) ................................................................. 4445

Clinical Studies


Contents continued on the preceding page
Experimental Studies

Glucocorticoids Augment Survival and Proliferation of Tumor Cells. S. GÜNDISCH, E. BOECKELER, U. BEHREND, E. AMTMANN, H. EHRHARDT, I. JEREMIAS (Munich; Heidelberg, Germany) .......................... 4251

uPA and uPA-Receptor Are Involved in Cancer-associated Myeloid-derived Suppressor Cell Accumulation. D. ILKOVIITCH, R. CARRIO, D.M. LOPEZ (Miami Beach; Miami, FL, USA) ........................................ 4263


siPGK1 Sensitizes Chemoresistant Human Ovarian Cancer Cell Lines to Cisplatin. C. LEPLEUX, E. ABEILARD-LEMOISSON, M. DUVAL, P. ICARD, H. LINCET (Caen, France) .................................. 4277

Antitumoral and Mechanistic Studies of Ianthelline Isolated from the Arctic Sponge Stryphnus fortis. K.Ø. HANNSEN, J.H. ANDERSEN, T. STIBERG, R.A. ENGH, J. SVENSON, A.-M. GENEVIÈRE, E. HANSEN (Breivika, Tromso; Norway; Banyuls Sur Mer, France) .......................................................... 4287

Cytostatic Activity of a 5-Fluoro-2’-deoxyuridine–Alendronate Conjugate Against Gastric Adenocarcinoma and Non-malignant Intestinal and Fibroblast Cell Lines. J. WEINREICH, T.C. SCHOTT, I. KÖNIGSRAINER, M. KÜPER, A. KÖNIGSRAINER, H. SCHOTT (Tübingen, Germany) .......................... 4299

Serum Folate: A Pharmacodynamic Biomarker of Intracellular Nitrosylcobalamin Activity Following Intravenous Administration in Dogs. A.M. SYSEL, W.I. HORNE, J.M. STEINER, J.S. SUCHODOLSKI, J.A. BAUER (Akron; Rootstown, OH; College Station, TX, USA) ........................................................ 4307

siRNA-mediated Inhibition of Antiapoptotic Genes Enhances Chemotherapy Efficacy in Bladder Cancer Cells. D. KUNZE, K. ERDMANN, M. FROEHNRE, M.P. WIRTH, S. FUESSEL (Dresden, Germany) .......................... 4313

IGF1R Gene Expression as a Predictive Marker of Response to Ionizing Radiation for Patients with Locally Advanced HPV16-positive Cervical Cancer. P. MORENO-ACOSTA, O. GAMBOA, M.S. DE GOMEZ, R. CENDALES, G.D. DIAZ, A. ROMERO, J.B. SERRA, Z. CONRADO, A. LEVY, C. CHARGARI, N. MAGNÉ (Bogotá, Colombia; Barcelona, Spain; Villejuif; Paris; Saint Priest en Jarez, France) .......................................................................................... 4319

Fluorescent Proteins Enhance UVC PDT of Cancer Cells. M. MOMIYAMA, A. SUETSUGU, H. KIMURA, H. KISHIMOTO, R. AKI, A. YAMADA, H. SAKURADA, T. CHISHIMA, M. BOUVET, N.N. BULGAKOVA, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan; Missouri, Russia) .................................................................................................................. 4327

Cancer-cell Killing by Engineered Salmonella Imaged by Multiphoton Tomography in Live Mice. A. UCHUGONOVA, M. ZHAO, Y. ZHANG, M. WEINIGEL, K. KÖNIG, R.M. HOFFMAN (San Diego, CA, USA; Saarbrücken; Jena, Germany) .................................................................................................................. 4331


Evaluation of MLH1 I219V Polymorphism in Unrelated South American Individuals Suspected of Having Lynch Syndrome. M.D. VALENTIN, F.C. DA SILVA, E.M. MONTEIRO SANTOS, S.D. DA SILVA, F. DE OLIVEIRA FERREIRA, S. AGUIAR JUNIOR, I. GOMY, C. VACCARO, M.A. REDAL, A. DELLA VALLE, C. SARROCA, L.J. RASMUSSEN, D.M. CARRARO, B.M. ROSSI (Lund, Sweden; Sao Paulo; Ribeirao Preto; Barretos, Brazil; Montreal, QC, Canada; Buenos Aires, Argentina; Montevideo, Uruguay; Copenhagen, Denmark) ........................................ 4347

Haptoglobin Phenotype and Epithelial Ovarian Cancer. V.D. MANDATO, E. MAGNANI, M. ABRATE, B. CASALI, D. NICOLI, E. FARNETTI, D. FORMISANO, D. PIRILLO, G. CIARLINI, P. DE IACO, I. STRADA, C. ZAMAGNI, G.B. LA SALA (Reggio Emilia; Bologna, Italy) .................................................................................................................. 4353